Ipsen announces new Vice President of Corporate External Communications

pharmafile | September 11, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing appointment, ipsen 

French biopharmaceutical group Ipsen has announced that Dr Ian Weatherhead has taken up the position of Vice President, Corporate External Communications.

Dr Weatherhead is well-equipped for the role, having worked in corporate communications roles for twenty years within the life sciences industry. He arrives at Ipsen from his previous tenure at Teva UK/Ireland where he lead the Corporate Communications and Government Affairs team. Earlier in his career, Dr Weatherhead has held global, regional and affiliate roles at other big industry players, including AstraZeneca, Sanofi, UCB and Sygenta.  

In his new role, Dr Weatherhead will be responsible for the design and implementation of an external corporate communications strategy which will connect with key external audiences to raise Ipsen’s corporate and brand awareness, while also supporting the firm’s development and growth.

Dr Weatherhead will report directly to Didier Veron, Senior Vice President, Public Affairs and Corporate Communications at Ipsen. On Weatherhead’s appointment, Veron commented: “I am delighted that Ian is joining the team to advance our external communications strategy as Ipsen continues its evolution into a leading global biopharmaceutical company focused on innovation and specialty care. He brings a wealth of experience in the pharmaceutical sector.”

Related Content

Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment

Ipsen and Medision Pharma have announced that Health Canada has approved Bylvay (odevixibat) for the …

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) …

FDA accepts Ipsen’s NDA for ultra-rare genetic disorder drug

The FDA have accepted Ipsen’s New Drug Application (NDA) for palovarotene, an oral, investigational, selective …

Latest content